证券代码：300110 证券简称：华仁药业 公告编号：2025-059 华仁药业股份有限公司 关于全资子公司盐酸异丙肾上腺素原料药获得上市申请 批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"盐 酸异丙肾上腺素"《化学原料药上市申请批准通知书》（通知书编号： 2025YS00767）。现将相关情况公告如下： 一、原料药登记信息 1．通用名称：盐酸异丙肾上腺素 2．英文名/拉丁名：Isoprenaline Hydrochloride 3．化学原料药注册标准编号：YBY68912025 4．包装规格：1kg/桶 5．申请事项：境内生产化学原料药上市申请 6．审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7．生产企业 名称：安徽恒星制药有限公司 地址：合肥市包河工业区纬五路 15 号 二、药品的其他情况 盐酸异丙肾上 ...

Group 1 - The company announced that its first extraordinary general meeting of shareholders for 2025 will be held on September 1, 2025 [2] - The meeting will review multiple proposals, including the election of an independent director for the eighth board of directors [2]

证券日报网讯 9月1日晚间，华仁药业发布公告称，近日，公司全资子公司安徽恒星制药有限公司收到 国家药品监督管理局核准签发的"盐酸奈福泮"《化学原料药上市申请批准通知书》。 （文章来源：证券日报） ...

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its subsidiary Anhui Hengxing Pharmaceutical to market "Nefopam Hydrochloride," a non-narcotic, non-addictive analgesic drug [1] Group 1: Product Approval - Anhui Hengxing Pharmaceutical has been granted the "Chemical Raw Material Drug Marketing Application Approval Notice" for Nefopam Hydrochloride, with notification number 2025YS00762 [1] Group 2: Product Characteristics - Nefopam Hydrochloride is a powerful analgesic with mild antipyretic and muscle relaxant effects, primarily used for treating acute pain, especially postoperative pain [1] - The drug can also serve as an adjunct in local anesthesia and needle anesthesia [1] - It is not classified as a psychoactive analgesic, thus eliminating concerns regarding addiction [1] Group 3: Clinical Usage - Nefopam Hydrochloride has been widely used in clinical settings for severe pain due to its effective pain relief, minimal side effects, and characteristics of rapid onset and prolonged action [1]

北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2025 年第一次临时股东会的 法律意见书 植德青（会）字[2025]0002 号 二〇二五年九月 山东省青岛市崂山区香岭路 1 号资源博雅广场 4 号楼 10 层 邮编：266000 10th Floor, Building 4, Resources Boya Plaza, No.1 Xiangling Road, Laoshan District, Qingdao City, Shandong Province 266000 P.R.C www.meritsandtree.com 北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2025 年第一次临时股东会的 法律意见书 植德青（会）字[2025]0002 号 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"）、《律师 事务所证券法律业务执业规则（试行）》（以下简称"《证券 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-057 华仁药业股份有限公司 2025 年第一次临时股东会决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载，误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决提案的情况； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开及召集情况 1、会议通知情况：华仁药业股份有限公司（以下简称"公司"）2025年8月16 日以董事会公告方式向全体股东发出召开2025年第一次临时股东会的通知。 2、会议召开时间： （1）现场会议召开时间：2025年9月1日14:00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025年9月1日上午9:15-9:25，9:30-11:30和下午13:00-15:00；通过深圳证 券交易所互联网投票系统投票的具体时间为：2025年9月1日上午9:15-下午15:00 期间的任意时间。 3、会议召开地点：山东省青岛市高科技工业园株洲路187号公司会议室。 4、会议召集人：公司董事会。 5、会议召开方式：采取现场投票与网络投票相结合的方式。 6、 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-058 地址：合肥市包河工业区纬五路 15 号 华仁药业股份有限公司 关于全资子公司盐酸奈福泮原料药获得上市申请批准 通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"盐 酸奈福泮"《化学原料药上市申请批准通知书》（通知书编号：2025YS00762）。 现将相关情况公告如下： 一、原料药登记信息 1．通用名称：盐酸奈福泮 6．审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7．生产企业 名称：安徽恒星制药有限公司 二、药品的其他情况 盐酸奈福泮为非麻醉性、非成瘾性强力镇痛药，兼有轻度的解热和肌松作用， 临床主要对症治疗急性疼痛，尤其是术后疼痛，亦可作为局部麻醉、针麻等麻醉 辅助用药。盐酸奈福泮不属于精神类镇痛药，不存在成瘾性；多年的临床实践亦 2．英文名 ...

Group 1 - The core viewpoint of the news is that Huaren Pharmaceutical experienced a decline in stock price and trading volume, with significant changes in financing and operational performance [1][2]. - On August 29, Huaren Pharmaceutical's stock fell by 2.06%, with a trading volume of 97.32 million yuan. The financing buy-in amount was 10.06 million yuan, while the net financing buy-in was 3.41 million yuan, indicating a relatively high financing balance of 237 million yuan, which accounts for 6.03% of the circulating market value [1]. - The company's main business revenue composition includes: basic infusion (40.63%), peritoneal dialysis fluid (34.90%), therapeutic preparations (14.92%), medical devices (8.14%), and others (1.41%) [1]. Group 2 - As of August 20, the number of shareholders of Huaren Pharmaceutical was 41,000, a decrease of 1.20% from the previous period, while the average circulating shares per person increased by 1.22% to 28,801 shares [2]. - For the first half of 2025, Huaren Pharmaceutical reported an operating income of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to the parent company of 37.33 million yuan, down 49.01% year-on-year [2]. - The company has distributed a total of 294 million yuan in dividends since its A-share listing, with cumulative distributions of 49.65 million yuan over the past three years [3].

Core Viewpoint - Hua Ren Pharmaceutical experienced a decline of 4.96% in stock price on August 27, with a trading volume of 174 million yuan, indicating potential market concerns regarding the company's performance and investor sentiment [1]. Financing Summary - On August 27, Hua Ren Pharmaceutical had a financing buy-in amount of 20.02 million yuan and a financing repayment of 20.01 million yuan, resulting in a net financing buy of -1,262 yuan [1]. - The total financing and securities balance for Hua Ren Pharmaceutical as of August 27 was 240 million yuan, which accounts for 5.88% of its circulating market value, indicating a relatively high level compared to the past year [1]. - The company had no short-selling activity on August 27, with a short-selling balance of 0.00 shares, suggesting a lack of bearish sentiment among investors [1]. Business Performance - As of August 20, the number of shareholders for Hua Ren Pharmaceutical was 41,000, a decrease of 1.20% from the previous period, while the average circulating shares per person increased by 1.22% to 28,801 shares [2]. - For the first half of 2025, Hua Ren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2]. Dividend Information - Since its A-share listing, Hua Ren Pharmaceutical has distributed a total of 294 million yuan in dividends, with 49.65 million yuan distributed over the past three years [3].

Core Viewpoint - Huarun Pharmaceutical is facing significant challenges, including a leadership change and its first loss since going public, primarily due to receivables and goodwill impairment [2][5][6]. Company Overview - Huarun Pharmaceutical was established in May 1998, focusing on the production and sales of narcotic injections, basic and therapeutic large-volume preparations, and medical devices [2]. - The company has been listed on the Shenzhen Stock Exchange's Growth Enterprise Market since 2010 [5]. Leadership Change - Chairman Zhang Li has been placed under residential surveillance and has resigned from his position after less than four months in office [2][3]. - The board has appointed director Hou Ruipeng to act as the chairman and legal representative temporarily [4]. Financial Performance - In 2024, the company reported a revenue of 1.353 billion yuan, a year-on-year decline of 17.30%, and a net loss attributable to shareholders of 1.368 billion yuan, a staggering drop of 827.67% [6]. - The company is experiencing its first loss since its IPO, attributed to receivables and goodwill impairment [5][6]. Receivables and Impairment Issues - Huarun Pharmaceutical's subsidiary, Qingdao Huarun Pharmaceutical Co., has a net receivable of approximately 1.348 billion yuan from China National Pharmaceutical Group, leading to a full credit impairment provision [7]. - The company plans to negotiate with China National Pharmaceutical Group regarding the collection of outstanding debts [7]. Sales and Revenue Decline - The overall sales volume of the company's products decreased by 9.46% in 2024, with self-produced drug revenue dropping by 9.43% [8]. - Despite growth in key products like peritoneal dialysis fluid and therapeutic preparations, their revenue contribution remains significantly lower than that of basic infusion products [8]. Recent Performance Trends - In the first half of 2025, the company continued to struggle, reporting a revenue of 624 million yuan, down 19.13%, and a net profit of 37.33 million yuan, a decline of 49.01% [9]. - The company's self-produced drug revenue for the reporting period was 564 million yuan, reflecting an 18.90% year-on-year decrease [11].